DOLUTEGRAVIR efficacy in HIV infected patients

1. Weller, I.V. & Williams, I.G. (2001). ABC of AIDS. Antiretroviral drugs. BMJ. 322(7299), 1410-1412Search in Google Scholar

2. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Retrieved from http://aidsinfo.nih.gov/guidelinesSearch in Google Scholar

3. Flexner, C. (1998). HIV protease inhibitors. N Engl J Med. 338, 1281-129310.1056/NEJM199804303381808Search in Google Scholar

4. "U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay". From: Reuters. 12 August 2013.Retrieved 13 February 2013Search in Google Scholar

5. EMA Tivicay information page. Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002753/human_med_001720. jsp&mid=WC0b01ac058001d124Search in Google Scholar

6. CSID: 25051637. (2014). Retrieved from http://www.chemspider.com/Chemical-Structure.25051637.htmlSearch in Google Scholar

7. Hare, S., Smith, S.J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S.H. & Cherepanov, P. (2011). Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 80(4), 565-57210.1124/mol.111.073189Search in Google Scholar

8. Cottrell, M.L., Hadzic, T. & Kashuba, A.D. (2013). Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 52(11), 981-99410.1007/s40262-013-0093-2Search in Google Scholar

9. FDA approves new drug to treat HIV infection. (2013). Retrieved from http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm364744.htmlSearch in Google Scholar

10. Min, S., Song, I. & Borland, J. et al. (2010). Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 54, 254-25810.1128/AAC.00842-09Search in Google Scholar

11. Song, I., Borland, J. & Chen, S. et al. (2012). Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 56, 1627-162910.1128/AAC.05739-11Search in Google Scholar

12. Letendre, S., Mills, A., Tashima, K., Thomas, D., Min, S., Chen, S., Song, I. & Piscitelli, S. (2013). Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results. CROI 2013. Poster 178LBSearch in Google Scholar

13. van Lunzen, J., Maggiolo, F., Arribas, J.R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J.K., Almond, S., Song, I., Brothers, C. & Min, S. (2012). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet Infect Dis. 12(2), 111-11810.1016/S1473-3099(11)70290-0Search in Google Scholar

14. Raffi, F., Rachlis, A., Stellbrink, H.J., Hardy, W.D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., Almond, S., Margolis, D., Brennan, C. & Min, S. (2013). SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviralnaive adults with HIV-1 infection: 48 week results from the randomized, double-blind, noninferiority SPRING-2 study. Lancet. 381(9868), 735-743 Search in Google Scholar

15. Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J.M., Baril, J.G., Domingo, P., Brennan, C., Almond, S. & Min, S. (2013). Extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, noninferiority trial. Lancet Infect Dis. 13(11), 927-935Search in Google Scholar

16. Walmsley, S.L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., Pappa, K., Wynne, B., Min, S. & Nichols, G. (2013). SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 369(19), 1807-1818Search in Google Scholar

17. Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., Harris, J., Brennan, C., Fujiwara, T. & Min, S. (2014). ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet. 383(9936), 2222-2231 Search in Google Scholar

18. Cahn, P., Pozniak, A.L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J.F., Richmond, G., Buendia, C.B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C.B., Lombaard, J., Grinsztejn, B., Dorey, D., Underwood, M., Griffith, S. & Min, S. (2013). Extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomized, doubleblind, non-inferiority SAILING study. Lancet. 382(9893), 700-708Search in Google Scholar

19. Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait- Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G. & Yeo, J.M. (2014). VIKING-3 Study Group. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 210(3), 354-362Search in Google Scholar

20. Eron, J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C. & Yeo, J. for the VIKING Study Group (2013). Safety and efficacy of dolutegravir in treatmentexperienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 207(5), 740-74810.1093/infdis/jis750356330723225901Search in Google Scholar

21. Cutillas, V., Mesplede, T., Anstett, K., Hassounah, S. & Wainberg, M.A. (2014). The addition of R262K to the H51Y mutation in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother. pii: AAC.04274-14. [Epub ahead of print]Search in Google Scholar

22. Hardy, I., Brenner, B., Quashie, P., Thomas, R., Petropoulos, C., Huang, W., Moisi, D., Wainberg, M.A. & Roger, M. (2014). Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. pii: dku387. [Epub ahead of print]Search in Google Scholar

23. Hightower, K.E., Wang, R., Deanda, F., Johns, B.A., Weaver, K., Shen, Y., Tomberlin, G.H., Carter, H.L. 3rd, Broderick, T., Sigethy, S., Seki, T., Kobayashi, M. & Underwood, M.R. (2011). Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 55(10), 4552-4559 10.1128/AAC.00157-11318700121807982Search in Google Scholar

24. Underwood, M.R., Johns, B.A., Sato, A., Martin, J.N., Deeks, S.G. & Fujiwara, T. (2012). The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults. J Acquir Immune Defic Syndr. 61(3), 297-30110.1097/QAI.0b013e31826bfd02380431222878423Search in Google Scholar

25. Johnson, M., Borland, J., Chen, S., Savina, P., Wynne, B. & Piscitelli, S. (2014). Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J ClinPharmacol. 78(5), 1043-104910.1111/bcp.12428424387824838177Search in Google Scholar

26. Simeprevir (2013). FDA Antiviral Drugs Advisory Committee Meeting Briefing DocumentSearch in Google Scholar

27. Sofosbuvir for the Treatment of Chronic Hepatitis C Infection, Gilead Sciences (2013). Retrieved from http://www.gilead.com/news/press-releases/2013/12/us-food-and-drugadministration-approves-gileads-sovaldisofosbuvir-for-the-treatment-of-chronichepatitis-cSearch in Google Scholar

28. Dow, D.E. & Bartlett, J.A. (2014). Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Infect Dis Ther. 3, 83-102 10.1007/s40121-014-0029-7426962625134686Search in Google Scholar